Pulmonary surfactant camouflage lipid nanoparticles for efficient mRNA lung delivery Authors: Weilun Sun, Ti-Qiang Zhou, Yuanyu Huang, Xing-Jie Liang, Fangzhou Li Published: 2026 Dear Editor, Lipid nanoparticles (LNPs)-based mRNA vaccines have played a pivotal role in curbing the Corona Virus Disease 2019 (COVID-19) pandemic and transformed the field of vaccine development.1 Inhaled vaccines, which can activate mucosal immunity in the respiratory tract, are capable of establishing protection at the first line of defense against viral infections.2 However, to date, no inhaled mRNA-LNP vaccine has successfully completed clinical trials. One critical factor contributing to the inconsistent efficacy of inhaled mRNA vaccines lies in the structural complexity of the respiratory mucosal barrier, which poses significant obstructions to nanoparticle delivery.3 Therefore, there is an urgent need to develop LNPs with mucosal residence and penetration capabilities to advance the clinical application of inhaled mRNA vaccines. Pulmonary surfactant (PS), composed of 80% lipids and 20% proteins, plays a crucial role in promoting gas exchange, clearing foreign substances and maintaining surface tension, which can also be internalized by alveolar epithelial cells and alveolar macrophages to regulate its homeostasis in the lung.4 Herein, we attempted to incorporate lipids derived from the pulmonary surfactant substance into LNPs to camouflage the LNPs, thereby involving them in PS recycling pathway and enhancing the efficiency of mRNA delivery to the lungs. By replacing the helper lipid of LNPs with dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), which is a major lipid component of pulmonary surfactant, we designed the surfactant camouflage strategy. This strategy enables LNPs to bind to surfactant protein A (SP-A), a kind of lectin in lung, which mediates the recycling of PS, thereby enhancing their retention in the mucosal layer.5 Additionally, binding of SP-A on the surface of LNPs increases the internalization of LNPs by alveolar epithelial cells (AECs), and then LNPs can undergo transcytosis to the inner side of the epithelial layer. Then we demonstrated that the surfactant camouflage strategy improved the inhaled vaccine to stimulate mucosal immunity and lung-resident T-cell immune responses, establishing stronger protection in the respiratory tract. Furthermore, we applied surfactant camouflage formulation to other FDA-approved LNPs and found that it consistently enhanced mRNA expression in the lungs. These findings demonstrate that surfactant camouflage is a universal strategy to improve the pulmonary delivery efficiency of inhaled LNPs, with the potential to advance the application of inhaled LNP-based drugs. To optimize the surfactant camouflage formulation, we designed five LNP compositions with different DPPC molar percentage (0% to 50%) based on the SM-102 LNPs formulation (Fig. 1a). We first characterized the physicochemical properties of different LNPs by dynamic light scattering (DLS). There were no significant differences in size, PDI and zeta potential for each type of LNPs (Supplementary Fig. 2a–c). The mRNA encapsulation efficiency of LNPs was higher than 80% when the DPPC content was below 30%. As the DPPC content increases, the decrease in ionizable lipid content reduces the N/P ratio of mRNA-LNP, thereby lowering the encapsulation efficiency of LNP for mRNA (Supplementary Fig. 2d and Supplementary Table 1). Next, we further evaluated the delivery efficiency of different formulations of mRNA-LNPs in vivo after pulmonary administration using IVIS imaging (Fig. 1a). Notably, the expression of mRNA delivered by LNP-2 was the highest, achieving twice the delivery efficiency of LNP-M (Supplementary Fig. 3). Based on these quantitative results, LNP-2 (formulated with 20% DPPC) was identified as the optimal surfactant camouflage formulation and was selected for further experimental investigations. LNP-2 did not exhibit significant cytotoxicity in AECs and alveolar macrophages (Supplementary Fig. 4). No apparent morphological differences were observed between LNP-M and LNP-2 by both transmission electron microscopy (Supplementary Fig. 5) and cryogenic electron microscopy (Supplementary Fig. 6). LNP-2 also exhibits stability at 4 °C and room temperature (Supplementary Figs. 7 and 8). Furthermore, we validated via pulmonary aerosol delivery that the engineered mRNA-LNPs maintained structural integrity against shear forces during nebulization while concurrently enhancing mRNA delivery efficiency in the lung (Supplementary Fig. 9). We further incorporated surfactant camouflage formulation into LNPs constructed with DLin-MC3-DMA and ALC-0315 as ionizable lipids to assess its impact on pulmonary mRNA delivery efficiency. The delivery efficiency of the modified LNPs was superior to that of the original formulations (Supplementary Fig. 10). The results also demonstrated the universality of surfactant camouflage strategy in multiple LNPs formulations.Fig. 1Formulation composition, mechanism exploration and application of pulmonary surfactant camouflage strategy. a Composition of LNPs based on SM-102 formulations with the molar percentage of DPPC varying from 0% (LNP-M), 10% (LNP-1), 20% (LNP-2), 30% (LNP-3), 40% (LNP-4), 50% (LNP-5). In vivo bioluminescence imaging at 12 h post intratracheal administration of mLuc-loaded LNPs (n = 3). b Pulmonary retention of DiD-labeled mRNA-LNPs. Representative confocal microscopy images of lung tissue showing the biodistribution of DiD-labeled mRNA-LNP-M and DiD-labeled mRNA-LNP-2 at day1 and day 3 post-inhalation. c Representative flow cytometry images of DCs in lung after inoculation with DiD-labeled EGFP mRNA loaded LNP via inhalation 12 h later. Quantification of DiD+ and EGFP+ cells in DCs (n = 3). d A schematic diagram of mouse immunization. Mice were vaccinated twice with the vaccine on day 0 and 14. Mouse serum was collected on Day 14, and mouse serum, BALF and lung tissue were collected on Day 28. Spike protein-specific IgG titers in serum and spike protein-specific IgA titers in BALF were detected by ELISA. Lung cells from mice were collected and stimulated with a spike peptide pool, and then detected for IFN-γ and TNF-α-positive T cells by flow cytometry (n = 8). Bars were presented as mean ± SD. c Statistical significance was determined by two-sided t-test. d Statistical significance was determined by one-way ANOVA with Tukey’s correction. A significant difference was considered at P < 0.05. Other supportive data are available in Figshare repository at 10.6084/m9.figshare.31524394 Formulation composition, mechanism exploration and application of pulmonary surfactant camouflage strategy. a Composition of LNPs based on SM-102 formulations with the molar percentage of DPPC varying from 0% (LNP-M), 10% (LNP-1), 20% (LNP-2), 30% (LNP-3), 40% (LNP-4), 50% (LNP-5). In vivo bioluminescence imaging at 12 h post intratracheal administration of mLuc-loaded LNPs (n = 3). b Pulmonary retention of DiD-labeled mRNA-LNPs. Representative confocal microscopy images of lung tissue showing the biodistribution of DiD-labeled mRNA-LNP-M and DiD-labeled mRNA-LNP-2 at day1 and day 3 post-inhalation. c Representative flow cytometry images of DCs in lung after inoculation with DiD-labeled EGFP mRNA loaded LNP via inhalation 12 h later. Quantification of DiD+ and EGFP+ cells in DCs (n = 3). d A schematic diagram of mouse immunization. Mice were vaccinated twice with the vaccine on day 0 and 14. Mouse serum was collected on Day 14, and mouse serum, BALF and lung tissue were collected on Day 28. Spike protein-specific IgG titers in serum and spike protein-specific IgA titers in BALF were detected by ELISA. Lung cells from mice were collected and stimulated with a spike peptide pool, and then detected for IFN-γ and TNF-α-positive T cells by flow cytometry (n = 8). Bars were presented as mean ± SD. c Statistical significance was determined by two-sided t-test. d Statistical significance was determined by one-way ANOVA with Tukey’s correction. A significant difference was considered at P < 0.05. Other supportive data are available in Figshare repository at 10.6084/m9.figshare.31524394 To investigate the mechanism of LNP-2 to enhance the efficiency of mRNA delivery in the lungs, we administered DiD-labeled mRNA-LNPs to mice by inhalation. Frozen section results showed that LNP-2 exhibited higher pulmonary retention on day 1 and day 3 (Fig. 1b and Supplementary Fig. 11). Fluorescence imaging also revealed that LNP-2 has a slower metabolic rate (Supplementary Fig. 12). Using flow cytometry, we found that AECs and DCs exhibited significantly higher internalization and EGFP mRNA expression of LNP-2 than LNP-M (Fig. 1c and Supplementary Fig. 13). LNP-2 also demonstrated higher mRNA expression in pulmonary immune cells (Supplementary Fig. 14). Additionally, higher uptake of LNP-2 was similarly observed in DCs from the lung-draining lymph node (Supplementary Fig. 15). Since SP-A can mediate PS into AECs for re-storage or degradation,4 we hypothesized that the different affinity of SP-A for LNPs was a key factor in increasing the internalization of LNPs by AECs. We verified that LNP-2 have higher specific affinity to SP-A by nano-flow cytometry (Supplementary Fig. 16) and surface plasmon resonance (SPR) (Supplementary Fig. 17). Binding of SP-A to LNPs has no effect on the physicochemical properties of LNPs (Supplementary Fig. 18). Then we co-incubated the SP-A and mRNA-LNPs to explore the impact of SP-A on the internalization of LNPs by AECs. The results from confocal microscopy and flow cytometry revealed that the uptake of LNP-2 by AECs was significantly increased when LNPs were pretreated with SP-A (Supplementary Fig. 19a–d). Moreover, SP-A also enhanced the efficiency of LNP-2 mRNA delivery into AECs (Supplementary Fig. 19e). Furthermore, SP-A-mediated uptake of LNP-2 by AECs exhibits both dose-dependent (Supplementary Fig. 20) and SP-A specific dependent (Supplementary Fig. 21). Then we modeled the positional distribution of AECs and DCs in the lungs by transwell for verifying whether mRNA-LNPs could be delivered to subepithelial DCs by uptake of AECs enhanced by transcytosis (Supplementary Fig. 22). The results indicated that SP-A-mediated uptake of LNPs by AECs enhanced the uptake of mRNA-LNPs by lower DCs (Supplementary Figs. 23 and 24) and the efficiency of mRNA expression (Supplementary Figs. 23 and 25). To further validate in vivo that enhanced AECs uptake improves LNP transmucosal transport efficiency, we pretreated mice with the endocytosis inhibitor prochlorperazine (PCZ) via intratracheal instillation to inhibit AECs endocytosis of LNPs. Results demonstrated that inhibition of AEC endocytosis significantly reduced LNP-2 distribution in the pulmonary interstitial region (Supplementary Fig. 26). These findings collectively indicate that surfactant camouflage strategy plays a crucial role in promoting LNP transmucosal transport by enhancing AEC-mediated internalization. To evaluate the immunoenhancing effect of the surfactant camouflage strategy in mRNA vaccines, we intratracheally administered 50 μL of SARS-CoV-2 Spike protein-encoding mRNA vaccine (100 μg/mL) delivered by either LNP-M or LNP-2 to mice on day 0 and day 14. The immune activation was subsequently assessed on day 28. First, we conducted tests on potential adverse reactions following vaccination. The results demonstrated that administration of the vaccine did not induce structural or functional impairment in major organs (Supplementary Figs. 27 and 28). Furthermore, no evidence of sustained neutrophil elevation or increased levels of inflammatory factors such as TNF-α and IL-6 in lung, IFN-β, CXCL10, and MCP-1 in BALF and serum was observed (Supplementary Figs. 29–33). Due to the higher uptake of LNP-2 by antigen-presenting cells (APCs), the vaccine formulated with LNP-2 as a carrier demonstrated enhanced maturation of APCs in both the lungs and lung-draining lymph nodes (Supplementary Figs. 34 and 35). After two immunizations, mouse serum, lung tissues, and bronchoalveolar lavage fluid (BALF) were collected to examine antigen-specific immune responses (Fig. 1d). We first measured the antigen-specific IgG titers in the serum following primary and booster immunizations using ELISA. The results showed that the mRNA vaccine delivered by LNP-2 induced significantly higher antigen-specific IgG titers compared to LNP-M (Fig. 1d). Similarly, higher titers of antigen-specific IgA (Fig. 1d) and IgG (Supplementary Fig. 36) were detected in the BALF. Furthermore, analysis of lung-resident T cells by flow cytometry revealed that surfactant camouflage strategy also enhanced antigen-specific cellular immune responses in the lungs (Fig. 1d and Supplementary Fig. 37). In addition, LNP-2 delivered mRNA vaccines also activated stronger antigen-specific T-cell immune responses in the spleen (Supplementary Fig. 38) as well as in lung-draining lymph nodes (Supplementary Fig. 39). Additionally, mRNA encoding non-antigenic sequences did not activate antigen-specific immune responses (Supplementary Figs. 40 and 41). Mice immunized with the LNP-2-delivered mRNA vaccine exhibited a significantly stronger immune response, which upon challenge with a SARS-CoV-2 pseudovirus, resulted in marked suppression of viral gene expression (Supplementary Fig. 42). Collectively, these findings demonstrated that surfactant camouflage strategy improves the protective efficacy of inhaled mRNA vaccines in the respiratory mucosa. In conclusion, we have developed surfactant camouflage strategy that involves incorporating DPPC (the major lipid component of PS) into LNP formulations. This approach significantly enhances the delivery efficiency of inhaled mRNA therapeutics. The strategy is applicable to diverse LNP systems and demonstrates a favorable safety profile. Moreover, surfactant-camouflaged LNPs facilitate more efficient transport across AECs, enhance DCs uptake, and ultimately potentiate the immune response elicited by mRNA vaccines. Collectively, our work proposes a novel and broadly applicable strategy for improving the delivery efficiency of inhaled mRNA-based therapeutics. Supplementary information Supplemental Materials for Pulmonary surfactant camouflage lipid nanoparticles for efficient mRNA lung delivery Supplemental Materials for Pulmonary surfactant camouflage lipid nanoparticles for efficient mRNA lung delivery